Trial reportStroke2022
Intensive Versus Standard Treatment of Hyperglycemia in Acute Ischemic Stroke Patient: A Randomized Clinical Trial Subgroups Analysis.
Trial report in Stroke, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Association between stress hyperglycemia and outcomes in patients with acute ischemic stroke due to large vessel occlusion.CNS neuroscience & therapeutics · 2023Trial
- Association between stress hyperglycemia ratio and early neurological deterioration after acute ischemic stroke: a retrospective cohort study.BMC neurology · 2026Article
- Systemic Inflammation Mediates the Association Between Admission Hyperglycemia and Pulmonary Infection or Prognosis in Acute Ischemic Stroke.Mediators of inflammation · 2026Article
- Stress hyperglycemia ratio and albumin predict in-hospital outcomes in patients with acute myocardial infarction: a cohort study.Scientific reports · 2025Observational
- Exploring the correlation between corrective glucose treatment and long-term patient outcomes: a SHINE secondary analysis.Frontiers in neurology · 2025Article
- Predictors of futile recanalization after endovascular therapy in anterior circulation stroke with large core infarction.Frontiers in neurology · 2025Article
- Fasting Blood Glucose on Prognosis After Acute Large Vessel Occlusion Reperfusion- A Multi-Center Study Based on Propensity Score Matching.Vascular health and risk management · 2025Article
- The glycemic gap as a prognostic indicator in cardiogenic shock: a retrospective cohort study.BMC cardiovascular disorders · 2024Observational
- Performance comparison of stress hyperglycemia ratio for predicting fatal outcomes in patients with thrombolyzed acute ischemic stroke.PloS one · 2024Article
- Impact of fasting blood glucose on prognosis after acute large vessel occlusion reperfusion: results from a multicenter analysis.Frontiers in neurology · 2024Article
- A review of stress-induced hyperglycaemia in the context of acute ischaemic stroke: Definition, underlying mechanisms, and the status of insulin therapy.Frontiers in neurology · 2023Review
- Diabetes and the treatment of ischemic stroke.Journal of diabetes and its complications · 2022Review
- The Role of Nondiabetic Hyperglycemia in Critically Ill Patients with Acute Ischemic Stroke.Journal of clinical medicine · 2022Article
- Clinical Significance of Stress Hyperglycemic Ratio and Glycemic Gap in Ischemic Stroke Patients Treated with Intravenous Thrombolysis.Clinical interventions in aging · 2022Article
- Recent advances in the prevention of secondary ischemic stroke: A narrative review.Brain circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundBenefit from blood glucose (BG) control during acute ischemic stroke may depend on glycemic parameters. We evaluated for associations between the SHINE (Stroke Hyperglycemia Insulin Network Effort) randomized treatment group and the SHINE predefined 90-day functional outcome, within-patient subgroups defined by various glycemic parameters.
methodsThe SHINE Trial randomized 1151 patients within 12 hours with acute ischemic stroke and hyperglycemia to standard (target BG 80-179 mg/dL) or intensive (target BG 80-130 mg/dL) BG control for 72 hours. We predefined 6 glycemic parameters: acute BG level, absence versus presence of diagnosed and undiagnosed diabetes, hemoglobin A1c, glycemic gap (acute BG-average daily hemoglobin A1c based BG), stress hyperglycemia ratio (acute BG/average daily hemoglobin A1c based BG), and BG variability (SD). Favorable functional outcome was defined by the SHINE Trial and based on the modified Rankin Scale score at 90 days, adjusted for stroke severity. We computed relative risks adjusted for baseline stroke severity and thrombolysis use.
resultsLikelihood for favorable outcome was lowest among patients with undiagnosed diabetes compared to patients with true nondiabetes (adjusted relative risk, 0.42 [99% CI, 0.19-0.94]). We did not find any relationship between the favorable outcome rate and baseline BG or any of the glycemic parameters. No differences between SHINE treatment groups were identified among any of these patient subgroups.
conclusionsIn this exploratory subgroup analysis, intensive versus standard insulin treatment of hyperglycemia in acute ischemic stroke patient subgroups, did not influence the 90-day functional outcomes, nor did we identify associations between these glycemic parameters and 90-day functional outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.